Following my earlier post on this issue, it is now reported that the Indian Patent Office (IPO) has refused patent to the anti-cancer drug, Abraxane. I am yet to obtain a copy of this IPO order.
A recap
Briefly, the opposition against the patent application for Abraxane was filed by Natco Pharma with the IPO and was decided against the patent applicant, Abraxis Biosciences (“Abraxis”). Abraxis appealed against the IPO’s order with the Intellectual Property Appellate Board (IPAB) owing to certain procedural lapses. IPAB agreed with Abraxis and asked the IPO to consider the opposition afresh.
What’s new?
The recent order of the IPO is said to have stated the following:
“The amended claims (here Abraxis Boisciences) lack inventive step and do not constitute an invention under the Patents Act, 1970.”
I will update this post and discuss the IPO’s order in detail once I peruse the order.
Raja Selvam
Founder & Managing Attorney, Selvam & Selvam | Practice areas include Trademarks, Patents, Domain names & Business law. Visiting faculty, Department of Journalism, Madras University where I teach copyrights & trademarks law. Passionate about entrepreneurship, start-ups, stocks, farming, technology and law.
What’s in a Shape – Protection of a Shape as a Design v. Trademark
One of the significant judgements from the recent time is the order of the Delhi High Court in the popular Crocs case. In an order dated March 6,…
Subsequent trade mark owner can claim ‘date of first use’ of its predecessor
The Bombay High Court ruled in favour of the plaintiff, Pidilite Industries Ltd., who had filed a trademark infringement suit against the defendant…
Trademark Dilution – All Dolled Up
If you, like me, were a kid of the 90s, you would instantly recall the hit song from being played to death on the radio and at every other birthday…